The latest report by IMARC Group, titled “Artificial Intelligence in Healthcare Market Report by Offering (Hardware, Software, Services), Technology (Machine Learning, Context Aware Computing, Natural Language Processing, and Others), Application (Robot-Assisted Surgery, Virtual Nursing Assistant, Administrative Workflow Assistance, Fraud Detection, Dosage Error Reduction, Clinical Trial Participant Identifier, Preliminary Diagnosis, and Others), End-User (Healthcare Providers, Pharmaceutical and Biotechnology Companies, Patients, and Others), and Region 2024-2032“, The global artificial intelligence in healthcare market size reached US$ 6.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 57.2 Billion by 2032, exhibiting a growth rate (CAGR) of 27.4% during 2024-2032.
Factors Affecting the Growth of the Artificial Intelligence in Healthcare Industry:
- Personalized Medicine Expansion:
The advancement of artificial intelligence (AI) is revolutionizing personalized medicine by enabling the creation of highly individualized treatment plans. AI systems analyze vast amounts of patient data, including genetic, environmental, and lifestyle information, to tailor therapies to each individual's unique profile. This approach enhances the precision of treatments, increasing their effectiveness while minimizing adverse effects. For instance, AI can identify genetic mutations linked to specific diseases, allowing for targeted therapies that address these mutations directly. Moreover, AI-driven models can predict how different patients will respond to various drugs, optimizing treatment regimens. Furthermore, the shift toward personalized medicine improves patient outcomes and helps avoid the trial-and-error approach traditionally used in prescribing treatments, leading to more efficient and effective healthcare delivery.
- Innovation in Drug Discovery:
AI is significantly transforming the drug discovery process by accelerating the identification of new drug candidates and reducing development costs. Additionally, traditional drug discovery involves extensive laboratory work and lengthy clinical trials, while AI technologies streamline this process by analyzing large datasets, such as genomic and proteomic information, to uncover potential drug targets. Moreover, machine learning algorithms can predict how new compounds will interact with biological systems, aiding in the identification of promising drug candidates more quickly than conventional methods. Furthermore, AI also helps in optimizing the chemical properties of these candidates to enhance their effectiveness and reduce side effects, thus contributing to market growth.
- Growth in Telemedicine:
The surge in telemedicine, driven in part by the COVID-19 pandemic is escalating the demand for AI-powered tools that facilitate remote healthcare services. Additionally, AI technologies enhance telemedicine by enabling remote consultations, diagnostics, and patient monitoring. For instance, AI algorithms can analyze patient symptoms and medical history during virtual consultations to assist physicians in diagnosing conditions more accurately. Moreover, AI-powered diagnostic tools can interpret medical images and lab results, providing real-time insights and recommendations. This technological support makes remote healthcare more effective and accessible, particularly for individuals in underserved or remote areas. As telemedicine continues to evolve, AI-driven tools play a crucial role in ensuring that remote care is as comprehensive and reliable as in-person visits, thus improving overall healthcare accessibility and convenience.
Competitive Landscape with Key Player:
- Amazon Web Services Inc.
- Cloudmedx Inc.
- DeepMind
- Enlitic Inc.
- General Vision Inc.
- Google Inc.
- International Business Machines
- iCarbonX
- Intel Corporation
- Medtronic
- Micron Technology Inc.
- Microsoft Corporation
- Next It Corporation
- Nuance Communications Inc.
- Nvidia Corporation
- Siemens Healthcare
- Welltok Inc.
Request Sample For PDF Report: https://www.imarcgroup.com/artifical-intelligence-healthcare-market/requestsample
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Offering:
- Hardware
- Software
- Services
Software represents the largest segment as it provides a broad range of functionalities that can be integrated into various healthcare processes, enhancing efficiency and decision-making.
Breakup by Technology:
- Machine Learning
- Context-Aware Computing
- Natural Language Processing
- Others
Machine learning accounts for the largest market share due to its advanced capabilities in analyzing complex healthcare data, predicting outcomes, and personalizing treatments.
Breakup by Application:
- Robot-Assisted Surgery
- Virtual Nursing Assistant
- Administrative Workflow Assistance
- Fraud Detection
- Dosage Error Reduction
- Clinical Trial Participant Identifier
- Preliminary Diagnosis
- Others
Clinical trial participant identifiers dominate the market growth as they streamline the recruitment and management of trial participants, which is crucial for the efficiency of clinical research.
Breakup by End-User:
- Healthcare Providers
- Pharmaceutical and Biotechnology Companies
- Patients
- Others
Pharmaceutical and biotechnology companies hold the largest market share as they are the primary developers and adopters of AI technologies for drug discovery, development, and personalized medicine.
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America’s dominance in artificial intelligence in the healthcare market is attributed to its advanced healthcare infrastructure, high adoption rates of new technologies, and substantial investment in AI research and development.
Global Artificial Intelligence in Healthcare Market Trends:
At present, healthcare providers are increasingly adopting AI technologies to enhance diagnostic accuracy, optimize treatment plans, and improve patient outcomes for imaging, pathology, and genomics. Additionally, AI is leveraged for predictive analytics to anticipate patient outcomes, identify high-risk patients, and personalize treatment plans which helps in early intervention and better management of chronic diseases. Furthermore, natural language processing (NLP) is being used to analyze unstructured data from medical records, research papers, and clinical notes which helps in extracting valuable insights, streamlining administrative tasks, and supporting clinical decision-making.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Comments
0 comment